Robert J. Gould - 01 Apr 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role: Director
Signature: /s/ Curt Oltmans, as attorney-in-fact for Robert J. Gould
Issuer symbol: FULC
Transactions as of: 01 Apr 2022
Transactions value $: -$1,537,756
Form type: 4
Filing time: 05 Apr 2022, 19:00:17 UTC
Next filing: 11 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FULC	Common Stock	Options Exercise	$270,197	+34,464	+6.8%	$7.84	541,094	01 Apr 2022	Direct	F1
transaction	FULC	Common Stock	Sale	-$828,159	-34,464	-6.37%	$24.03^*	506,630	01 Apr 2022	Direct	F1, F2
transaction	FULC	Common Stock	Options Exercise	$56,722	+7,235	+1.43%	$7.84	513,865	04 Apr 2022	Direct	F1
transaction	FULC	Common Stock	Sale	-$173,749	-7,235	-1.41%	$24.02^*	506,630	04 Apr 2022	Direct	F1, F3
transaction	FULC	Common Stock	Options Exercise	$412,007	+52,552	+10.37%	$7.84	559,182	05 Apr 2022	Direct	F1
transaction	FULC	Common Stock	Sale	-$1,274,774	-52,552	-9.4%	$24.26^*	506,630	05 Apr 2022	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FULC	Stock Option (right to buy)	Options Exercise	$0	-34,464	-10.62%	$0	289,998	01 Apr 2022	Common Stock	34,464	$7.84	Direct	F1, F5
transaction	FULC	Stock Option (right to buy)	Options Exercise	$0	-7,235	-2.49%	$0	282,763	04 Apr 2022	Common Stock	7,235	$7.84	Direct	F1, F5
transaction	FULC	Stock Option (right to buy)	Options Exercise	$0	-52,552	-18.59%	$0	230,211	05 Apr 2022	Common Stock	52,552	$7.84	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.17, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5	This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.